azathioprine and Rhinitis studies

Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.

Rhinitis: Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.

Research Excerpts

Excerpt	Relevance	Reference
" This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN)."	9.24	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. ( Agard, C; Baron, G; Bienvenu, B; Bourgarit, A; Cohen, P; Crestani, B; Delbrel, X; Diot, E; Geffray, L; Godmer, P; Groh, M; Guillevin, L; Le Guern, V; Le Jeunne, C; Lifermann, F; Limal, N; Liozon, E; Mékinian, A; Mouthon, L; Néel, A; Pagnoux, C; Papo, T; Puéchal, X; Quémeneur, T; Ravaud, P; Ruivard, M; Ruppert, AM; Sailler, L; Saraux, JL; Terrier, B, 2017)
" This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN)."	5.24	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. ( Agard, C; Baron, G; Bienvenu, B; Bourgarit, A; Cohen, P; Crestani, B; Delbrel, X; Diot, E; Geffray, L; Godmer, P; Groh, M; Guillevin, L; Le Guern, V; Le Jeunne, C; Lifermann, F; Limal, N; Liozon, E; Mékinian, A; Mouthon, L; Néel, A; Pagnoux, C; Papo, T; Puéchal, X; Quémeneur, T; Ravaud, P; Ruivard, M; Ruppert, AM; Sailler, L; Saraux, JL; Terrier, B, 2017)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors[NCT00647166]			Phase 3	114 participants (Actual)	Interventional	2008-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

azathioprine and Rhinitis

Research Excerpts

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Puéchal, X	2
Pagnoux, C	2
Baron, G	2
Quémeneur, T	2
Néel, A	2
Agard, C	2
Lifermann, F	2
Liozon, E	1
Ruivard, M	2
Godmer, P	1
Limal, N	2
Mékinian, A	1
Papo, T	1
Ruppert, AM	1
Bourgarit, A	1
Bienvenu, B	1
Geffray, L	2
Saraux, JL	2
Diot, E	1
Crestani, B	1
Delbrel, X	1
Sailler, L	1
Cohen, P	2
Le Guern, V	1
Terrier, B	2
Groh, M	1
Le Jeunne, C	2
Mouthon, L	2
Ravaud, P	2
Guillevin, L	2
Wislez, M	1
Cottin, V	1
Aouba, A	1
Bonnotte, B	1
Leirisalo-Repo, M	1